Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 in Advanced Thymoma and Thymic Carcinoma
NCT00965250Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2009
- Primary completion
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in thymoma, thymic carcinoma (TC), sponsored by National Cancer Institute. Started Aug 2009; status: completed.
02
Drugs
cixutumumab
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT00965250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00965250.